EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Assessing the Immunological Safety of Silk Fibroin Nanoparticles: An In Vitro Study With Primary Human Immune Cells

Beatriz Rodrigues, Ana B. Ramos, Sónia Silva, Rui F. P. Pereira, Ana C. Fonseca, Arménio C. Serra, Jorge F. J. Coelho, Maria T. Cruz, Rita G. Fonseca

Advanced Healthcare Materials · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

ABSTRACT Biomaterials for drug delivery must be biodegradable, nontoxic, and must not trigger inflammatory or immune responses. Silk fibroin (SF) is a natural polymer with exceptional mechanical strength and notable biological properties. In this study, the immunogenicity and inflammatory responses of silk fibroin nanoparticles (SFNPs) were characterized in primary human cells for the first time. SFNPs with a mean particle size of 213 ± 9 nm were synthesized and characterized. Primary human immune cells were exposed to SFNPs at concentrations ranging from 0.1 to 0.01 mg/mL. Cell viability remained above 80% under the tested conditions. No significant immune recognition was detected. Additionally, the levels of key pro‐inflammatory proteins, including inducible nitric oxide synthase, pro‐interleukin‐1 β , and cyclooxygenase‐2, did not show significant upregulation compared to the control. Biodegradability assays demonstrated that SFNPs underwent degradation within 20 days, under physiological conditions. These findings indicate that SFNPs exhibit bio‐inert behavior and highlight the significant advantages of SF as a biomaterial for biomedical applications. Owing to these properties, SFNPs represent a versatile biomaterial for the next‐generation of drug delivery systems, offering substantial potential for improving clinical outcomes across a wide range of therapeutic areas.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Beatriz Rodrigues, Ana B. Ramos, Sónia Silva, Rui F. P. Pereira, Ana C. Fonseca, Arménio C. Serra, Jorge F. J. Coelho, Maria T. Cruz, Rita G. Fonseca
Quelle
Advanced Healthcare Materials
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2192-2640, 2192-2659
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Beatriz Rodrigues, Ana B. Ramos, Sónia Silva, Rui F. P. Pereira, Ana C. Fonseca, Arménio C. Serra, Jorge F. J. Coelho, Maria T. Cruz, Rita G. Fonseca (2026). Assessing the Immunological Safety of Silk Fibroin Nanoparticles: An In Vitro Study With Primary Human Immune Cells. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71687
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1 · Lizenz 2